Is FATE THERAPEUTICS INC (FATE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 50.3% / 30% | 131.7% / 30% | 0.6% / 30% | 166.3% / 5% | ✗ NOT HALAL |
| DJIM | 50.3% / 33% | 131.7% / 33% | 0.6% / 33% | 166.3% / 5% | ✗ NOT HALAL |
| MSCI | 24.4% / 33% | 63.9% / 33% | 0.3% / 33% | 166.3% / 5% | ✗ NOT HALAL |
| S&P | 50.3% / 33% | 131.7% / 33% | 0.6% / 33% | 166.3% / 5% | ✗ NOT HALAL |
| FTSE | 24.4% / 33% | 63.9% / 33% | 0.3% / 50% | 166.3% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -2455.9% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -51.8% | |
| Return on Assets (ROA) | -24.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$106M |
| Free Cash Flow | -$112M |
| Total Debt | $78M |
| Debt-to-Equity | 37.6 |
| Current Ratio | 5.8 |
| Total Assets | $319M |
Price & Trading
| Last Close | $1.23 |
| 50-Day MA | $1.25 |
| 200-Day MA | $1.17 |
| Avg Volume | 1.6M |
| Beta | 2.2 |
|
52-Week Range
$0.66
| |
About FATE THERAPEUTICS INC (FATE)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is FATE THERAPEUTICS INC (FATE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), FATE THERAPEUTICS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is FATE THERAPEUTICS INC's debt ratio?
FATE THERAPEUTICS INC's debt ratio is 50.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.4%.
What are FATE THERAPEUTICS INC's key financial metrics?
FATE THERAPEUTICS INC has a market capitalization of $136M, and revenue of $7M. Return on equity stands at -51.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.